Advanced Cancer Clinical Trial
Official title:
The Impact of Acute Delirium On the Level of Distress In Patients With Advanced Cancer and Their Caregivers
Primary Objectives:
1. To determine the proportion of patients who experience partial or complete recollection
of symptoms of delirium and the level of distress associated with this recall.
2. To determine caregiver's level of distress associated with the patient's episode of
delirium.
Informed Consent for Patients:
Delirium is often seen in patients with advanced cancer. Delirium is defined as confusion
and restlessness. In this study, cancer patients will be asked about their memory of
experiencing delirium and the distress related to those memories. Caregivers of those
patients will also be asked to participate, and they will be asked questions about their
experience during these situations.
You will be tested using the Memorial Delirium Assessment Scale to see if you have recovered
from your delirium. If you are still eligible to take part in this study, and both you and
your caregiver agree to participate in this study; you will be asked by the research nurse
to complete several questionnaires that ask questions about your mental state, any memory of
experiencing delirium, the severity of the delirium, symptoms you experienced during the
delirium episode, and your level of emotional distress related to that event. If you and
your caregiver are asked to participate in this study; you will also be asked "open-ended"
questions (questions with no wrong answers) regarding the experience you had during the
severe episode of delirium; your memories of the experience, and the overall distress
related to it. This conversation will be tape recorded, and it will be written down
word-for-word, for the purpose of analysis. The conversation is expected to last no more
than 30 minutes.
The assessments and questionnaires will be conducted only at the time of interview. No
further assessments or questions will be done after the completion of the study. All
information collected for the study will be kept confidential. You will be assigned a study
participant number when you enroll on the study, and this number will be used (instead of
your name) on all data collections, to protect your confidentiality.
This is an investigational study. Up to 100 patients and 100 caregivers will take part in
this study. All will be enrolled at M. D. Anderson.
Informed Consent for Caregivers:
Delirium is often seen in patients with advanced cancer. Delirium is defined as confusion
and restlessness.
In this study, you will be asked about your memory of your family member's experience of
delirium, and the distress related to those memories. The patient you are caring for will
also be asked to participate, and they will be asked questions about their experience during
these situations.
If you are eligible to take part in this study, and both you and your family member agree to
participate in this study, you will be asked by the research nurse to complete several
questionnaires that ask questions about your family member's mental state, your memory of
your family member's experience of delirium, the severity of the delirium, symptoms your
family member experienced during the delirium episode, and your level of emotional distress
related to that event. If you and your caregiver are asked to participate in this study; you
will also be asked "open-ended" questions (questions with no wrong answers) regarding the
experience you had during your family member's severe episode of delirium, your memories of
the experience, and the overall distress related to it. This conversation will be recorded
using a tape recorder, and it will be written down word for word, for the purpose of
analysis. The conversation is expected to last no more than 30 minutes.
The assessments and questionnaires will be conducted only at the time of interview. No
further assessments or questions will be done after the completion of the study. All
information collected for the study will be kept confidential. You will be assigned a study
participant number when you enroll on the study, and this number will be used (instead of
your name) on all data collections, to protect your confidentiality.
This is an investigational study. Up to 100 cancer patients and 100 caregivers will take
part in this study. All will be enrolled at M. D. Anderson.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 |